ESR1 and breast carcinoma: Re-introduction of the ERα in breast cancer by 5-aza 2′dC or TSA restores oestrogen responsiveness and sensitivity to current anti-oestrogen modalities, and provides additional therapeutic targets in the form of DNMT1 or HDACs (Yang et al., 2001).